Bosentan

Latest News for: bosentan

Edit

Latest Update 2021: Global Tracleer (bosentan) Market With COVID-19 Impact Analysis | Top Growing Companies ...

The Sentinel Newspaper 25 Jun 2021

Global Tracleer (bosentan) Market Key Players, Business Approaches And Geographical Analysis Amid COVID-19 Pandemic ... Report on the Global Tracleer (bosentan) Market is a cradle for all the market-related details right from the finances, regional development to the future market growth rate.

Edit

Alembic Pharma gets USFDA final approval for Bosentan Tablets; stock up 1.5%

IIFL 24 Jan 2020

Bosentan Tablets, 62.5 mg and 125 mg have an estimated market size of $68mn for twelve months ending September 2019, according to IQVIA ... .

Edit

Tracleer (bosentan; Johnson & Johnson) Drug Overview 2018: The First Oral Therapy to be Developed ...

Business Wire 26 Jun 2019

DUBLIN--(BUSINESS WIRE)--The "Tracleer" report has been added to ResearchAndMarkets.com's offering. Tracleer (bosentan; Johnson & Johnson) was the first oral therapy to be developed specifically for the treatment of PH ... Analyst Outlook Once the market leader and the first- ... .

Edit

Tracleer (bosentan; Johnson & Johnson) Drug Overview & Product Profiles 2016-2025

PR Newswire 26 Jun 2019

Tracleer (bosentan; Johnson & Johnson) was the first oral therapy to be developed specifically for the treatment of PH ... Once the market leader and the first-to-market drug for pulmonary hypertension (PH), Tracleer (bosentan; Johnson & Johnson), will now be succeeded by ...

Edit

Teva Announces Launch of a Generic Version of Tracleer� (bosentan) Tablets in the United States

Business Wire 19 Jun 2019

TEVA) today announced the launch of a generic version of Tracleer�1 (bosentan) tablets, 62.5 mg and 125 mg, in the U.S. Bosentan Tablets are an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group 1) in adults to improve exercise ability and to decrease worsening of the condition ... .

Edit

Teva Announces Launch of a Generic Version of Tracleer® (bosentan) Tablets in the United States

Public Technologies 19 Jun 2019

'The launch of Bosentan Tablets in the U.S ... Elevations of liver aminotransferases (ALT, AST) and liver failure have been reported with bosentan.Bosentan is likely to cause major birth defects if used by pregnant females based on animal data.Therefore, pregnancy must be excluded before the start of treatment with Bosentan Tablets.

Edit

Natco Pharma receive USFDA approval for generic Bosentan Tablets; stock up ~1%

IIFL 02 May 2019

The tablets of Natco marketing by its partner Lupin are a generic version of Actelion Pharmaceuticals Ltds Tracleer tablets in the same strengths ... .

Edit

Lupin in alliance with Natco gets FDA nod for Bosentan tablets

IIFL 02 May 2019

According to IQVIA MAT data released in March 2019, Bosentan Tablets, 62.5 mg, and 125 mg had annual sales of ~$84.8mn ... .

Edit

Lupin gains as co receives USFDA approval for Bosentan tablets

Moneycontrol 02 May 2019

Bosentan tablets is the generic version of Actelion Pharmaceuticals Tracleer Tablets, 62.5 mg and 125 mg ... Bosentan tablets is the generic version of Actelion Pharmaceuticals Tracleer Tablets, 62.5 mg and 125 mg, as per ... Bosentan ...

Edit

Actelion Receives FDA Approval for TRACLEER® (bosentan) for use in Pediatric Patients with Pulmonary Arterial Hypertension

Public Technologies 08 Sep 2017

About TRACLEER® (bosentan). TRACLEER® (bosentan), an orally available endothelin receptor antagonist, was the first oral treatment approved for PAH ... In females who are or may become pregnant With cyclosporine A With glyburide In patients who are hypersensitive to bosentan or any component of TRACLEER.

Edit

Actelion Receives FDA Approval Of TRACLEER® (bosentan) For Use In Pediatric Patients With Pulmonary Arterial Hypertension

PR Newswire 06 Sep 2017

SOUTH SAN FRANCISCO, Calif., Sept. 6, 2017 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that the U.S. Food and Drug Administration (FDA) has approved a new 32 mg tablet for oral suspension for ... .

Edit

Bosentan Hydrate (CAS 157212-55-0) - Global and Chinese Market Report 2011-2021 - Research and Markets

Business Wire 22 Aug 2016

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Bosentan Hydrate (CAS 157212-55-0) Global and Chinese Market Report - 2016" report to their offering ... The report provides key statistics on the market status of the Bosentan Hydrate manufacturers an ...

Edit

Bosentan (CAS 147536-97-8) Market Global and Chinese Report 2016-2021 - Research and Markets

Business Wire 19 Aug 2016

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Bosentan (CAS 147536-97-8) Global and Chinese Market Report - 2016" report to their offering ... The report provides key statistics on the market status of the Bosentan manufacturers and is a valuable source of guidanc ...

Edit

Actelion provides an update on the bosentan study - COMPASS 2 (Actelion Ltd)

noodls 17 Mar 2014

ATLN) today announced the results of COMPASS-2, a Phase IV, prospective, randomized, double-blind, placebo-controlled, event-driven study evaluating the effect of bosentan on the time to first morbidity or mortality event in patients with symptomatic pulmonary arterial hypertension (PAH) already treated with sildenafil.

Edit

Actelion Ltd.: Bosentan Studies In Pulmonary Fibrosis Show No Effect On Primary Exercise Improvement Endpoint

Stockhouse 28 Nov 2005

In the IPF study BUILD-1, although not statistically significant, positive trends were observed for pre-defined secondary endpoints, such as the combined incidence of death or treatment failure at 12 months (36.1% in the placebo group versus 22.5% in the bosentan group; p=0.076; 95% CL 0.37, 1.05), representing a relative risk reduction of 38%.